Insurer WellPoint plans online care option
WellPoint plans to build a network of primary care doctors and specialists who will be available any time to consult with
patients.
Health Care Businesses
Articles
Arcadia sees smaller quarterly, fiscal-year losses
Despite losses, company sees growth in its DailyMed pharmacy services, which packages the right dosages of prescriptions to
make it easier for patients to follow their regimens.
Research reforms will force Lilly, others to test how drugs stack up
The federal government is currently doling out $1.1 billion in stimulus funds to pay for research that compares multiple medical
treatments against one another to determine which is most effective. Drug companies like Eli Lilly and Co. are wary that comparative-effectiveness
research could threaten their sales.
Erbitux fails to stop colon cancer before it spreads
Eli Lilly and Co. and Merck KGaA drug failed to slow tumors in a study designed to expand the medicine’s use to patients whose
disease is in an earlier stage.
Genetic testing could spur Erbitux drug sales
The drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
Cancer researcher battling Semafore in court
Former collaborator alleges firm breached its agreement with him and refused to pay royalty income.
Moody’s lowers Eli Lilly outlook to ‘negative’
Moody's Investors Service on Friday lowered its rating outlook on drugmaker Eli Lilly and Co. to "negative"
from "table" due in part to the looming expiration of patents protecting key drugs from generic competition.
Eli Lilly invests in $250M Australian venture fund
The unnamed venture fund will be based in Brisbane, and will focus on biotechnology investments in Australia and southeastern
Asia.
Health care suppliers need to think long term, expert says
Companies in the health care supply chain need to engage in more strategic, long-term preparation even as the industry faces
uncertainties and upheaval, MIT expert tells local conference attendees.
Arcadia Resources says it will add 930 jobs
Executives of the health care services provider will be joined by Gov. Mitch Daniels and Mayor Greg Ballard for a Thursday
morning announcement at the company's headquarters.
Lilly still waiting on once-weekly Byetta
The U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering an approval decision on the
drug Bydureon to Oct. 22. The previous deadline was in March.
Latest Lilly job cuts target marketing employees
Indianapolis-based drugmaker Eli Lilly and Co. is on course to cut 5,500 jobs by the end of 2011 in a bid to eliminate $1
billion in annual expenses.
Judge rejects controversial Guidant plea agreement
The deal included a $296 million criminal fine, but no charges against executives who failed to properly report problems with the company's defibrillators.
TAYLOR: Reform will drive demand for health care facilities
There has been a noticeable uptick in the level of health care real estate development activity this year.
Startup sees big potential for ‘ouchless’ medical tests
Companion Diagnostics wants to detect early warning signs of chronic diseases.
Medco Health profits climb as it adds big clients
Medco, which operates a major pharmacy and distribution center in Whitestown, got a boost from higher prices on brand-name
drugs and from greater sales of more profitable generic drugs.
Clarian hospital system regains its appetite to build
Clarian is planning to spend $1.7 billion in the next five years on capital projects, half of that going to its downtown Indianapolis
campuses.
Lilly sets date for move from Faris campus downtown
Work force reductions, new business structure make leased office space unnecessary. Moves will begin in late June.
Lilly diabetes drug may have cancer risk, FDA says
Once-weekly form of Byetta is awaiting the FDA’s OK. Analyst predict the new version of the drug, if approved, could rack
up sales of $2 billion annually.
Louisiana gets $20M in Lilly drug settlement
Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for
uses that had not been approved by federal regulators.